{
    "symbol": "DERM",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-15 11:46:02",
    "content": " Cost of goods sold increased by $4.3 million to $8.2 million for the 3-month period ended March 31, 2022 and is primarily due to a higher sales volume of $10.1 million versus first quarter sales in 2021, incremental royalties of Qbrexza that has a higher royalty rate that will decrease notably in Q2, a gross profit of $12.6 million from product revenue was 61% and reflects the end of the step up costs for Qbrexza that expired in Q4 of 2021."
}